WO1997011936A1 - Preparation of carboxyalkyl derivatives - Google Patents
Preparation of carboxyalkyl derivatives Download PDFInfo
- Publication number
- WO1997011936A1 WO1997011936A1 PCT/US1996/015672 US9615672W WO9711936A1 WO 1997011936 A1 WO1997011936 A1 WO 1997011936A1 US 9615672 W US9615672 W US 9615672W WO 9711936 A1 WO9711936 A1 WO 9711936A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- 6alkyl
- substituted
- aryl
- hydroxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *N(c(cccc1)c1N1)C1=O Chemical compound *N(c(cccc1)c1N1)C1=O 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N O=C1Oc(cccc2)c2N1 Chemical compound O=C1Oc(cccc2)c2N1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/18—Preparation of optical isomers by stereospecific synthesis
Definitions
- Stromelysin aka. proteoglycanase, matrix metal loproteinase-3 (MMP-3), procollagenase activator, "transin”
- collagenase aka. interstitial collagenase, matrix metalloproteinase- 1 (MMP-1)
- gelatinase aka.
- type IV collagenase, matrix metal loproteinase-2 (MMP-2), 72kDa-gelatinase or type V collagenase, matrix metal loproteinase-9, (MMP-9), 92kDa-gelatinase) are metalloendoproteinases secreted by fibroblasts and chondrocytes, and are capable of degrading the major connective tissue components of articular cartilage or basement membranes. See G.M. McGeehan et al., Nature 370. 558 (94); A.J.H Gearihg et al., Nature 37Q, p555 (94); K.M. Mohler et al., Nature 370, p218 (94) and EP274,234.
- OA osteoarthritis
- RA rheumatoid arthritis
- DMARD's Disease modifying antirheumatic drugs
- NSAIDs Generic nonsteroidal antiinflammatory drugs
- Stromelysin and collagenase inhibitors are also believed to have utility in preventing articular cartilage damage associated with septic arthritis, controlling tumor metastasis, optionally in combination with current chemotherapy and/or radiation. See L.M. Matrisian, G.T. Bowden, P. Krieg, G. Furstenberger, J.P. Briand, P. Leroy, R. Breathnach, "The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors", Proc. Natl. Acad. Sci.. USA. 83, 9413-7 (1986); S.M. Wilhelm, I.E. Collier, A. Kronberger, A.Z. Eisen, B.L. Manner, G.A.
- the inhibitors described in Scheme I are prepared as follows. An arylalkyl carboxylic acid is first converted to its corresponding acid chloride using oxallyl chloride and this is used to acylate lithio-4-benzyl-2-oxazolidinone. The derived imide is then enolized with Cl3Ti(Oi-Pr) in the presence of Hunig's base and alkylated with t-butyl acrylate. The chiral auxilliary is then remove with lithium hydroperoxide and the resulting acid ester enolized with lithium diisoprpyl amide and alkylated with an alkyl halide.
- This invention is concemed with a novel process for the preparation of carboxyalkyl derivatives of Formula I (wherein R l , R2, R3, AA and X are described below) which are useful inhibitors of matrix metalloendoproteinase-mediated diseases including degenerative diseases (such as defined above) and certain cancers.
- the instant process offers selectivity in the alkylation step by not producing isomeric products that require column chromatography for
- the instant invention encompasses the process of making a compound of Formula I
- Rl is hydrogen, mono or disubstituted Ci-Ralkyl, C ⁇ _6alkoxy or substituted C2-8 alkenyl wherein the substituents are independently selected from the group consisting of:
- Aryl wherein the Aryl group is selected from the group consisting of
- Ra and Rb are each independently hydrogen; Aryl or heteroaryl and mono and di-substituted aryl or heteroaryl as defined above; or substituted C l -6alkyl wherein the substitutent is selected from hydroxy, halo, and aryl or heteroaryl, or wherein Ra and Rb are joined such that together with the nitrogen and carbon atoms to which they are attached, there is formed a saturated or unsaturated Iactam or benzolactam ring such as wherein n is 1 , 2 or 3 or benzo fused Iactam ring such as
- the Iactam portion thereof is a ring of 5, 6, 7 or 8 atoms, said Iactam or benzolactam to have a single hetero atom;
- R a and Rb are each independently hydrogen; aryl or heteroaryl and mono and di-substituted aryl or heteroaryl as defined above; or substituted C i-6alkyl wherein the substitutent is selected from hydroxy, halo, and aryl, or wherein R a and Rb are joined such that together with the nitrogen and carbon atoms to which they are attached, there is formed a saturated or unsaturated lactim (or imide) such as
- lactim portion thereof is a ring of 5, 6, 7 or 8 atoms, said lactim or benzolactim to have a single hetero atom;
- Ra and Rb are each independently hydrogen; or Cl-6 Alkyl; aryl as defined above or ArylC ⁇ -6Alkyl or mono or di substituted ArylC ⁇ -6Alkyl wherein the substitutents are independently selected from Cl-6alkyl, Cl-6alkyloxy, halo, hydroxy, amino, Cl-6alkylamino, aminoCl-6alkyl, carboxyl, carboxylCl-6alkyl, and Cl-6 alkylcarbonyl and Aryl is defined above; or wherein Ra and Rb are joined such that together with the nitrogen and oxygen atoms to which they are attached, there is formed a saturated or unsaturated monocyclic urethane or benzofused cyclic urethane such as
- urethane ring contains 5, 6, 7 or 8 atoms, said ring to contain 2 heteroatoms
- R a , Rb, and R c are each independently hydrogen; or Cl-6 Alkyl; or ArylC ⁇ -6 Alkyl or mono or di substituted ArylC ⁇ -6Alkyl wherein the substitutents are independently selected from C ⁇ _6alkyl, Ci -6alkyloxy, halo, hydroxy, amino, Cl-6alkylamino, aminoCi -6alkyl, carboxyl, carboxylCi_6alkyl, and C i -6alkylcarbonyl and aryl is defined as above; or wherein R and Rb are joined such that together with the nitrogen atoms to which they are attached, there is formed a saturated or unsaturated monocyclic urea or benzofused cyclic urea such as
- urea ring contains up to 8 atoms, said ring to contain 2 heteroatoms; or Rb and Rc are joined such that together with the nitrogen atom to which they are attached, there is formed a saturated or unsaturated monocyclic ring or benzofused ring containing 5, 6, 7 or 8 atoms, said ring to contain 1 heteroatom;
- Ra and Rb are each independently hydrogen; or Cl-6
- sulfonamide ring contains 5, 6, 7 or 8 atoms, said ring to contain 2 heteroatoms;
- Ra and Rb are each independently hydrogen; or Cl -6
- Ra and Rb are each independently hydrogen; or Cl -6
- R2 is Cl- 12 alkyl, arylCl-4alkyl, aryl substituted Ci -4alkyl, (arylCi-
- aryl group is selected from the group consisting of:
- Z is a pharmaceutically counterion, such as sodium, potassium, calcium or magnesium
- substituted phenyl wherein the substitutent is carboxy, carboxyC l -3alkyl, aminocarbonyl, C l -6alkylaminocarbonyl;
- AA is a single bond or an amino acid of formula II
- Rf and Rg are individually selected from:
- X is 6 wherein R5 and R6 are each individually selected from the group consisting of:
- the unsaturated rings such as those described in definitions R l (d), (e), (g), (h), (i), (j) and (k) are intended to include rings wherein a double bond is present at one, two or more of the available positions.
- the term aryl C ⁇ -6 alkyl as found in definitions such as Rl (g), (h), (i), (j) and (k) are intended to describe aryl and aryl Cl-6 alkyl.
- aryl Cl -4 alkyl- aryl Cl -4 arkyl
- aryl Cl-4 alkyl group wherein the aryl is substituted as aryl Cl-4 alkyl- such as -CH2 phenyl.
- Ri , R 2 AA, and X are as described herein
- Preparation of compound 14 comprises adding to a solution containing solvents, belonging to a group consisting of dichloromethane, benzene, toluene, cyclohexane, heptane, EDC, or other carbodiimides, and the like, a carboxylic acid of the formula (9):
- a preferred process of the invention encompasses the process of making a compound of formula I
- Rl is substituted Cl -8 alkyl
- R2 is Cl-12 alkyl, arylC l -4alkyl, aryl substituted Cl -4alkyl, (arylCi-4alkyl)-arylCi-4alkyl, or biarylC ⁇ oalkyl wherein the substituent is Cl -3alkyl or hydroxy, and wherein the aryl group is selected from the group consisting of:
- R3 is (a) H
- substituted phenyl wherein the substitutent is carboxy, carboxyC 1 -3 alkyl, aminocarbonyl, C l -6alkylaminocarbonyl;
- AA is a single bond or an amino acid of formula II
- Rf and Rg are individually selected from
- X is 6 wherein R5 and R6 are each individually selected from the group consisting of:
- Lithium aluminum hydride (20.2 mL; 1.0 M in THF) was added to a stirred solution of (1) (3.84 g, 20.2 mmol) in THF (20 mL) at 0 °C. The solution was stirred at room temperature for 2 h and quenched sequentially with water (0.77 mL), 15% NaOH (0.77 mL), and water (2.3 mL). The resulting suspension was filtered, and the filtrate was evaporated to dryness. The residue was partitioned between CH2CI2 and brine, and the organic layer was separated, dried, and concentrated to a liquid (2.29 g, 70%):
- EXAMPLE (6) L-Prolinol 4-(n-Propyl phenylbutanamide l -(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC; 5.58 g, 29.1 1 mmol) was added to a solution of 4- (t ⁇ -propyl)phenylbutanoic acid (5.0 g, 24.24 mmol) and (5)-2- pyrrolidinemethanol (L-prolinol; 2.39 mL, 24.35 mmol) in dichloromethane (30 mL), and the reaction mixture was stirred at room temperature overnight.
- EDC n-Propyl phenylbutanamide l -(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
- the reaction mixture was stirred at this temperature for 3 h and at room temperature for 2 h over which time the dark red color faded to a pale yellow color.
- the reaction was quenched with saturated ammonium chloride (200 mL). The two layers were separated, and the aqueous layer was back extracted with CH2CI2 (2 x). The combined organic extracts were washed with aqueous NaHC ⁇ 3, brine, dried, and evaporated to a yellow oil.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Carboxy-peptidyl compounds of formula (I) are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, coronary thrombosis associated with atherosclerotic plaque rupture, and aneurysmal aortic disease. This invention relates to a process of making the carboxy-peptidyl compounds of formula (I).
Description
TITLE QF THE INVENTION
PREPARATION OF CARBOXY ALKYL DERIVATIVES
BACKGROUND OF THE INVENTION
The development of new methods for the preparation of carboxyalkyl derivatives is of continuing importance, since these compounds have interesting biological activity and are useful as inhibitors of matrix metalloendoproteinase and in the treatment of matrix metal loendoproteinase-mediated diseases.
Stromelysin (aka. proteoglycanase, matrix metal loproteinase-3 (MMP-3), procollagenase activator, "transin"), collagenase (aka. interstitial collagenase, matrix metalloproteinase- 1 (MMP-1)), and gelatinase (aka. type IV collagenase, matrix metal loproteinase-2 (MMP-2), 72kDa-gelatinase or type V collagenase, matrix metal loproteinase-9, (MMP-9), 92kDa-gelatinase) are metalloendoproteinases secreted by fibroblasts and chondrocytes, and are capable of degrading the major connective tissue components of articular cartilage or basement membranes. See G.M. McGeehan et al., Nature 370. 558 (94); A.J.H Gearihg et al., Nature 37Q, p555 (94); K.M. Mohler et al., Nature 370, p218 (94) and EP274,234. Elevated levels of both enzymes have been detected in joints of arthritic humans and animals: K.A. Hasty, R.A. Reife, A.H. Kang, J.M. Stuart, "The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis", Arthr. Rheum.. 33, 388-97 (1990); S.M. Krane, E.P. Amento, M.B. Goldring, S.R. Goldring, and M.L. Stephenson, "Modulation of matrix synthesis and degradation in joint inflammation", The Control of Tissue Damage. A.B. Glauert (ed.), Elsevier Sci. Publ.. Amsterdam, 1988, Ch. 14, pp 179-95; A. Blanckaert, B. Mazieres, Y. Eeckhout, G. Vaes, "Direct extraction and assay of collagenase from human osteoarthritic cartilage", Clin. Chim. Acta. 185 73-80 (1989). Each enzyme is secreted from these cells as an inactive proenzyme which is subsequently activated. There is evidence that stromelysin may be the in vivo activator for collagenase, implying a cascade for degradative enzyme activity: A. Ho, H. Nagase, "Evidence that human rheumatoid synovial matrix
metalloproteinase 3 is an endogenous activator of procollagenase", Arch Biochem Biophvs.. 267, 21 1 -16 (1988); G. Murphy, M.I. Crockett, P.E. Stephens, B.J. Smith, A.J.P. Docherty, "Stromelysin is an activator of procollagenase", Biochem. J.. 248, 265-8 (1987); Y. Ogata, J.J. Engh. Id, H. Nagase, "Matrix metalloprotease-3 (stromelysin) activates the precusor for human matrix metalloproteinase-9," J. Biol. Chem. 267, 3581 -84 (1992). Inhibiting stromelysin could limit the activation of collagenase and gelatinase as well as prevent the degradation of proteoglycan.
The disability observed in osteoarthritis (OA) and rheumatoid arthritis (RA) is largely due to the loss of articular cartilage. No therapeutic agent in the prior art is known to prevent the attrition of articular cartilage in these diseases.
"Disease modifying antirheumatic drugs" (DMARD's), i.e., agents capable of preventing or slowing the ultimate loss of joint function in OA and RA are widely sought. Generic nonsteroidal antiinflammatory drugs (NSAIDs) may be combined with such agents to provide some relief from pain and swelling.
There is extensive literature on the involvement of these metalloproteinases in arthritis. That stromelysin inhibition may be effective in preventing articular cartilage degradation has been demonstrated in vitro by measuring the effect of matrix metal loendoproteinase inhibitors on proteoglycan release from rabbit cartilage explants: CB. Caputo, L.A. Sygowski, S.P. Patton, D.J. Wolanin, A. Shaw, R.A. Roberts, G. DiPasquale, J. Orthopaedic Res.. 6, 103-8 (1988).
Stromelysin and collagenase inhibitors are also believed to have utility in preventing articular cartilage damage associated with septic arthritis, controlling tumor metastasis, optionally in combination with current chemotherapy and/or radiation. See L.M. Matrisian, G.T. Bowden, P. Krieg, G. Furstenberger, J.P. Briand, P. Leroy, R. Breathnach, "The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors", Proc. Natl. Acad. Sci.. USA. 83, 9413-7 (1986); S.M. Wilhelm, I.E. Collier, A.
Kronberger, A.Z. Eisen, B.L. Manner, G.A. Grant, E.A. Bauer, G. I. Goldberg, "Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells", Ibid.. 84, 6725-29 (1987); Z. Werb et aL, "Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression", J. Cell Biol.. 109, 872-889 (1989): L.A. Liotta, CN. Rao, S.H. Barsky, "Tumor invasion and the extracellular matrix", Lab. Invest.. 49, 636-649 (1983); R. Reich, B. Stratford, K. Klein, G. R. Martin, R. A. Mueller, G. C Fuller, "Inhibitors of collagenase IV and cell adhesion reduce the invasive activity of malignant tumor cells", in Metastasis: Ciba Foundation Symposium; Wiley, Chichester, 1988, pp. 193-210; controlling periodontal diseases, such as gingivitis, V.J. Uitto, R. Applegren, PJ. Robinson, "Collagenase and neutral metalloproteinase activity in extracts of inflammed human gingiva", J. Periodontal Res.. 16, 417-424(1981); degrading structural components of the glomerular basement membrane (GBM) of the kidney, the major function of which is to restrict passage of plasma proteins into the urine; W.H. Baricos, G. Murphy, Y. Zhou, H.H. Nguyen, S.V. Shah, "Degradation of glomerular basement membrane by purified mammalian metalloproteinases", Biochem. J.. 254, 609-612 (1988); preventing the rupture of atherosclerotic plaques leading to coronary thrombosis, A.M. Henney, P.R. Wakeley, M.J. Davies, K. Foster, R. Hembry, G. Murphy, S. Humphries, "Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization". Proc. Nat'l. Acad. Sci. USA. 88, 8154-8158 (1991 ); preventing or delaying the degradation of the connective tissue matrix that stabilizes the atherosclerotic plaques, thereby preventing events leading to acute coronary thrombosis; treating degenerative aortic disease associated with thinning of the medial aortic wall; and degrading other in vivo substrates including the inhibitors αi - proteinase inhibitor and may therefore influence the activities of other proteinases such as elastase: P. G. Winyard, Z. Zhang, K. Chidwick, D. R. Blake, R. W. Carrell, G. Murphy, "Proteolytic inactivation of human αi -antitrypsin by human stromelysin", FEBS Letts.. 279, 1 , 91 -94 (1991).
An approach to the synthesis of carboxyalkyl derivatives is disclosed in PCT WO 94/12169 and is depicted in Scheme 1 as follows:
SCHEME 1
The inhibitors described in Scheme I are prepared as follows. An arylalkyl carboxylic acid is first converted to its corresponding acid chloride using oxallyl chloride and this is used to acylate lithio-4-benzyl-2-oxazolidinone. The derived imide is then enolized with Cl3Ti(Oi-Pr) in the presence of Hunig's base and alkylated with t-butyl acrylate. The chiral auxilliary is then remove with lithium
hydroperoxide and the resulting acid ester enolized with lithium diisoprpyl amide and alkylated with an alkyl halide. The acid is then coupled to an amine and the t-butyl ester deprotected with trifluoroacetic acid to afford the desired inhibitors. However, this approach involves an alkylation step that results in an approximately 3:1 mixture of products, which then has to be separated by column chromatography via their esters.
SUMMARY OF THE INVENTION
This invention is concemed with a novel process for the preparation of carboxyalkyl derivatives of Formula I (wherein R l , R2, R3, AA and X are described below) which are useful inhibitors of matrix metalloendoproteinase-mediated diseases including degenerative diseases (such as defined above) and certain cancers.
The instant process offers selectivity in the alkylation step by not producing isomeric products that require column chromatography for
Q spenpaarraattiinonn.
DETAILED DESCRIPTION OF THE INVENTION
The instant invention encompasses the process of making a compound of Formula I
or a pharmaceutically acceptable salt thereof wherein:
Rl is hydrogen, mono or disubstituted Ci-Ralkyl, Cι _6alkoxy or substituted C2-8 alkenyl wherein the substituents are independently selected from the group consisting of:
(a) hydrogen,
(b) carboxy,
(c) aminocarbonyl,
(d) Cl -6alkoxy,
(e) Cl -6alkylcarbonyl,
(f) Aryl wherein the Aryl group is selected from the group consisting of
(1 ) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) furyl,
(5) pyrryl,
(6) thienyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
(10) tetrazolyl,
(1 1) pyrazinyl,
(12) pyrimidyl,
(13) quinolyl,
(14) isoquinolyl,
(15) benzofuryl,
(16) isobenzofuryl,
(17) benzothienyl,
(18) pyrazolyl,
(19) indolyl,
(20) isoindolyl,
(21) purinyl,
(22) carbazolyl,
(23) isoxazolyl,
(24) thiazolyl,
(25) oxazolyl,
(26) benzthiazolyl, and
(27) benzoxazolyl, and mono and di-substituted Aryl as defined above in items (1) to (27) wherein the substitutents are independently selected from Cl -6alkyl, Cl - 6alkyloxy, halo, hydroxy, amino, Cl -6alkylamino, aminoCl -6alkyl, carboxyl, carboxylCl-6alkyl, and Cl -6alkylcarbonyl;
(g) aryloxy wherein the aryl groups are defined above;
(h) aroyl wherein the aryl groups are defined above;
(i)
O N — C — Rb
Ra wherein Ra and Rb are each independently hydrogen; Aryl or heteroaryl and mono and di-substituted aryl or heteroaryl as defined above; or substituted C l -6alkyl wherein the substitutent is selected from hydroxy, halo, and aryl or heteroaryl, or wherein Ra and Rb are joined such that together with the nitrogen and carbon atoms to which they are attached, there is formed a saturated or unsaturated Iactam or benzolactam ring such as
wherein n is 1 , 2 or 3 or benzo fused Iactam ring such as
wherein the Iactam portion thereof is a ring of 5, 6, 7 or 8 atoms, said Iactam or benzolactam to have a single hetero atom;
())
O
wherein Ra and Rb are each independently hydrogen; aryl or heteroaryl and mono and di-substituted aryl or heteroaryl as defined above; or substituted C i-6alkyl wherein the substitutent is selected from hydroxy, halo, and aryl, or wherein Ra and Rb are joined such that together with the nitrogen and carbon atoms to which they are attached, there is formed a saturated or unsaturated lactim (or imide) such as
or benzolactim (or imide) ring such as
wherein the lactim portion thereof is a ring of 5, 6, 7 or 8 atoms, said lactim or benzolactim to have a single hetero atom;
(k) amino and mono or disubstituted amino wherein the substituent is selected from C l-6 alkyl and Aryl where aryl or heteroaryl is defined above;
0)
o
-N — C — O — Rb
Wherein Ra and Rb are each independently hydrogen; or Cl-6 Alkyl; aryl as defined above or ArylCθ-6Alkyl or mono or di substituted ArylCθ-6Alkyl wherein the substitutents are independently selected from Cl-6alkyl, Cl-6alkyloxy, halo, hydroxy, amino, Cl-6alkylamino, aminoCl-6alkyl, carboxyl, carboxylCl-6alkyl, and Cl-6 alkylcarbonyl and Aryl is defined above; or wherein Ra and Rb are joined such that together with the nitrogen and oxygen atoms to which they are attached, there is formed a saturated or unsaturated monocyclic urethane or benzofused cyclic urethane such as
wherein the urethane ring contains 5, 6, 7 or 8 atoms, said ring to contain 2 heteroatoms;
(m)
O
-N — C — N — R^
Ra c
Wherein Ra, Rb, and Rc are each independently hydrogen; or Cl-6 Alkyl; or ArylCθ-6 Alkyl or mono or di substituted ArylCθ-6Alkyl wherein the substitutents are independently selected from C ι_6alkyl, Ci -6alkyloxy, halo, hydroxy, amino, Cl-6alkylamino, aminoCi -6alkyl, carboxyl, carboxylCi_6alkyl, and C i -6alkylcarbonyl and aryl is defined as above; or wherein R and Rb are joined such that together with the nitrogen atoms to which they are attached, there is formed a saturated or unsaturated monocyclic urea or benzofused cyclic urea such as
wherein the urea ring contains up to 8 atoms, said ring to contain 2 heteroatoms; or Rb and Rc are joined such that together with the nitrogen atom to which they are attached, there is formed a saturated or unsaturated monocyclic ring or benzofused ring containing 5, 6, 7 or 8 atoms, said ring to contain 1 heteroatom;
(n)
O
■N — S — R^
Ra O
Wherein Ra and Rb are each independently hydrogen; or Cl-6
Alkyl; or ArylCθ-6Alkyl or mono or di substituted ArylCO- 6Alkyl wherein the substitutents are independently selected from Cl-6alkyl, Cl -6alkyloxy, halo, hydroxy, amino, Cι _ 6alkylamino, aminoCl-6alkyl, carboxyl, carboxylCi-6alkyl, and C l -6alkylcarbonyl and Aryl is defined as above or wherein Ra and Rb are joined such that together with the nitrogen and sulfer atoms to which they are attached, there is formed a saturated or unsaturated monocyclic sulfonaminde or benzofused cyclic sulfonamide such as
.so2
-N /
(CH2)n
or
wherein the sulfonamide ring contains 5, 6, 7 or 8 atoms, said ring to contain 2 heteroatoms; (o)
O
II C — N — Rb
a
Wherein Ra and Rb are each independently hydrogen; or Cl -6
Alkyl; or ArylCθ-6Alkyl or mono or di substituted ArylCO- 6Alkyl wherein the substitutents are independently selected from Cl -6alkyl, Cl-6alkyloxy, halo, hydroxy, amino, Cl- 6alkylamino, aminoCl-6alkyl, carboxyl, carboxyICl -6alkyl, and Cl-6alkylcarbonyl and Aryl is defined as above; or Ra and Rb are joined such that together with the nitrogen atom to which they are attached, there is formed a saturated or unsaturated monocyclic ring or benzofused ring containing 5, 6, 7 or 8 atoms, said ring to contain 1 heteroatom;
(P) o
II
■S — N — Rr
O R-
Wherein Ra and Rb are each independently hydrogen; or Cl -6
Alkyl; or ArylCθ-6Alkyl or mono or di substituted ArylCO- 6Alkyl wherein the substitutents are independently selected from Cl -6alkyl, Cl-6alkyloxy, halo, hydroxy, amino, Cl -
όalkylamino, aminoCl-6alkyl, carboxyl, carboxylCl -6alkyl, and Cl-6alkylcarbonyl and Aryl is defined as above; or Ra and Rb are joined such that together with the nitrogen atom to which they are attached, there is formed a saturated or unsaturated monocyclic ring or benzofused ring containing up to 8 atoms, said ring to contain 1 heteroatom;
R2 is Cl- 12 alkyl, arylCl-4alkyl, aryl substituted Ci -4alkyl, (arylCi-
4alkyl)-arylCi-4alkyl, or biarylC ι oalkyl wherein the substituent is Cl -
3alkyl or 1 lydroxy, and wherein the aryl group is selected from the group consisting of:
(1) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) pyrryl,
(5) furyl,
(6) thienyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
(10 ) tetrazolyl,
(I F ) pyrazinyl,
(IT ) pyrimidyl,
(i 3: ) quinolyl,
(i4: ) isoquinolyl,
(i5 ) benzofuryl,
(i ; ) isobenzofuryl,
(i7: ) benzothienyl,
(18' ) pyrazolyl,
(19 ) indolyl,
(2o; ) isoindolyl,
(2i : ) purinyl,
(22: ) carboxazolyl,
(23 ) isoxazolyl,
(24) thiazolyl,
(25) oxazolyl,
(26) benzthiazolyl, and
(27) benzoxazolyl, and mono and di-substituted Aryl as defined above in items (1) to (27) wherein the substitutents are independently selected from Ci-6alkyl, Cl 6alkyloxy, hydroxyCi oalkyl, Ci-6alkoxyCι oalkyl, halo, hydroxy, amino, Cl -6alkylamino, aminoCι _6alkyl, carboxyl, carboxylCl -6alkyl, and Ci-βalkylcarbonyl;
R3 is
(a) H,
(b) Z, where Z is a pharmaceutically counterion, such as sodium, potassium, calcium or magnesium,
(c) Cl -lθalkyl,
(d) Aryl or Aryl Cl-3alkyl, wherein the aryl group is selected from the group consisting of
(1 ) phenyl, and
(2) substituted phenyl, wherein the substitutent is carboxy, carboxyC l -3alkyl, aminocarbonyl, C l -6alkylaminocarbonyl;
AA is a single bond or an amino acid of formula II
wherein Rf and Rg are individually selected from:
(a) hydrogen,
(b) Cl -oalkyl,
(c) mercapto Ci-6alkyl,
(d) hydroxy Cι _6alkyl,
(e) carboxy Ci -6alkyl,
(f) amino substituted C2-6alkyl
(g) aminocarbonyl Ci-6alkyl,
(h) mono- or di-C l -6alkyl amino C2-6alkyl,
(i) guanidino C2-6alkyl,
(j) substituted phenyl Cl-6alkyl, wherein the substitutent is hydrogen.hydroxy, carboxy, Cl-4 alkyl, or Cl-4alkyloxy, (k) substituted indolyl Cl-6alkyl, wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Cl-4alkyloxy, (1) substituted imidazolyl C2-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl -4 alkyl, or Ci-4alkyloxy, (m) substituted pyridyl Cl-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Cl -4alkyloxy, (n) substituted pyridylamino Cl-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or
Cl-4alkyloxy, (o) substituted pyimidinyl Cl-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Cl -4alkyloxy,
Rs I
X is 6 wherein R5 and R6 are each individually selected from the group consisting of:
(a) H,
(b) Cl-ioalkyl,
(c) Aryl or ArylCi-6alkyl, wherein the aryl group is selected from the group consisting of
(1 ) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) pyrryl,
(5) furyl,
(6) thienyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
( 10) tetrazolyl,
(1 1 ) pyrazinyl,
(12) pyrimidyl,
(13) quinolyl,
(14) isoquinolyl,
(15) benzofuryl,
(16) isobenzofuryl,
(17) benzothienyl,
(18) pyrazolyl,
(19) indolyl,
(20) isoindolyl,
(21) purinyl,
(22) carbazolyl,
(23) isoxazolyl,
(24) benzthiazolyl,
(25) benzoxazolyl,
(26) thiazolyl, and
(27) oxazolyl. and mono and di-substi tuted Aryl as defined above in items (1 ) to (27) wherein the substituten ts are independently selected from Cl-6alkyl, Cl -
6alkyloxy, halo, hydro- κ;y, amino, C l -6alkylamino, aminoC l -6alky 1, carboxyl, carboxylCl -6alkyl, and Cl -6alkylcarbonyl comprising adding a compound of formula * )
9 wherein R2 is described as above, and L-prolinol to a solvent, while maintaining a temperature of about 20°C to about 30°C to produce a solution containing a compound of structural formula 6
10 + wherein R2 is described above, adding to the solution a strong base in an ether in the presence of DMPU, cooling the solution to from about -100°C to -50°C, adding a solution of a protected alkyl halide 5 , wherein Rl is described above, and warming the solution to from about -40°C to about -20°C to produce a solution containing a compound of structural formula 11
For purposes of this specification, and as appreciated by those of skill in the art, the unsaturated rings such as those described in definitions R l (d), (e), (g), (h), (i), (j) and (k) are intended to include rings wherein a double bond is present at one, two or more of the available positions. Similarly, the term aryl Cθ-6 alkyl, as found in definitions such as Rl (g), (h), (i), (j) and (k) are intended to describe aryl and aryl Cl-6 alkyl. Similarly the term (aryl Cl -4 alkyl-) aryl Cl -4 arkyl, is intended to describe as aryl Cl-4 alkyl group wherein the aryl is substituted as aryl Cl-4 alkyl- such as -CH2 phenyl.
Compounds of the instant invention are conveniently prepared using the procedures described generally below and more explicitly described in the Example section thereafter. The novel process of this invention can be depicted as shown in the following schemes I, and II below:
SCHEME I
2 N Hcl, THF 2h, rt
BnO
R' = Bn, Methyl or H R 1 = described herein
SCHEME π
LDA, DMPU, THF
10 -80~>-40~>-20C
Ri , R2 AA, and X are as described herein
Compounds of structural formula 5 are known. See N. Gruenfeld et al., J. Med. Chem., 26, 1277-1282 (1983) and O. Branca and A. Fischli, Helv. Chim. Actα,_60, 925-944 (1977).
Preparation of compound 14 comprises adding to a solution containing solvents, belonging to a group consisting of dichloromethane, benzene, toluene, cyclohexane, heptane, EDC, or other carbodiimides, and the like, a carboxylic acid of the formula (9):
wherein R2 is described as above, and L-prolinol, while maintaining a temperature of about 20°C to about 30°C for about 3 to about 36 hours to produce a solution containing a compound of structural formula 10
wherein and R2 is described herein, adding to the solution a strong base such as LDA, LiN(SiMe3)2, KN(SiMe3)2 and the like, in tetrahydrofuran (THF) or other ethers such as ethyl ether, methyl propyl ether and the like, in the presence of DMPU and the like, cooling the solution to from about -100°C to -50°C, preferrably from about -90°C to -75°C, adding a solution of a protected alkyl halide 5, wherein Rl is described above, and warming the solution to from about -40°C to about -20°C for about 1 to about 30 hours to produce a solution containing a compound of structural formula 11
wherein R 1 , R2 and are described herein, adding to a solution containing a compound of structural formula 11 in THF-H20 mineral acids such as
HC1 or H2S04, and the like, wherein the amount of mineral acid in the solution is from about 2 to about ION, and heating the solution to from about 50°C to about 100°C for about 30 minutes to about 24 hours to produce a solution containing a compound of structural formula 12
wherein R 1 , R2 and R' are described herein, coupling the compounds of structural formula 12 with an amino acid followed by hydrolysis to produce a compound of structural formula 13
wherein R l , R2, R', AA, and X are described herein, oxidizing a compound of structural formulal3 at a temperature of about -10°C to about 2°C using a Jones reagent to produce a compound of structural formula 14
wherein Rl , R2 AA, and X are described herein.
A preferred process of the invention encompasses the process of making a compound of formula I
or a pharmaceutically acceptable salt thereof wherein:
Rl is substituted Cl -8 alkyl;
R2 is Cl-12 alkyl, arylC l -4alkyl, aryl substituted Cl -4alkyl, (arylCi-4alkyl)-arylCi-4alkyl, or biarylC ι oalkyl wherein the substituent is Cl -3alkyl or hydroxy, and wherein the aryl group is selected from the group consisting of:
(1 ) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) pyrryl,
(5) furyl,
(6) thienyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
(10) tetrazolyl,
(1 1) pyrazinyl,
(12) pyrimidyl,
(13) quinolyl,
(14) isoquinolyl,
(15) benzofuryl,
( 16) isobenzofury 1,
(17) benzothienyl,
(18) pyrazolyl,
(19) indolyl,
(20) isoindolyl,
(21) purinyl,
(22) carboxazolyl,
(23) isoxazolyl,
(24) thiazolyl,
(25) oxazolyl,
(26) benzthiazolyl, and
(27) benzoxazolyl, and mono and di-substituted Aryl as defined above in items (1) to (27) wherein the substitutents on the aryl group are independently selected from Cl-6alkyl, Cl-6alkyloxy, hydroxyCl-6alkyl, Ci-6alkoxyCl -6alkyl, halo, hydroxy, amino, Ci-6alkylamino, aminoCl-6alkyl, carboxyl, carboxylCi -6alkyl, and Cl -6alkylcarbonyl;
R3 is (a) H,
(b) Z, where Z is a pharmaceutically acceptable counterion,
(c) Ci-ioalkyl,
(d) Aryl or Aryl Cl-3alkyl, wherein the aryl group is selected from the group consisting of
(1 ) phenyl, and
(2) substituted phenyl, wherein the substitutent is carboxy, carboxyC 1 -3 alkyl, aminocarbonyl, C l -6alkylaminocarbonyl;
AA is a single bond or an amino acid of formula II
(a) hydrogen,
(b) Cι _6alkyl,
(c) mercapto Cι_6alkyl,
(d) hydroxy Cι _6alkyl,
(e) carboxy Cι_6alkyl,
(f) amino substituted C2-6alkyl
(g) aminocarbonyl C i -βalk yi,
(h) mono- or di-Cl-6alkyl amino C2-6alkyl,
(i) guanidino C2-6alkyl,
(j) substituted phenyl Cl -6alkyl, wherein the substitutent is hydrogen-hydroxy, carboxy, Cl -4 alkyl, or Ci-4alkyloxy, (k) substituted indolyl C l _6alkyl, wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Ci -4alkyloxy, (1) substituted imidazolyl C2-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Ci -4alkyloxy, (m) substituted pyridyl Cl -6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Ci-4alkyloxy, (n) substituted pyridylamino Cl-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or
Cl-4alkyloxy, (o) substituted pyrimidinyl Cl -6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or
Ci -4alkyloxy,
■?« --
X is 6 wherein R5 and R6 are each individually selected from the group consisting of:
(a) H,
(b) Cl -lθalkyl,
(c) Aryl or ArylCi-6alkyl, wherein the aryl group is selected from the group consisting of
(1) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) pyrryl,
(5) furyl,
(6) thienyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
(10) tetrazolyl,
(1 1) pyrazinyl,
(12) pyrimidyl,
(13) quinolyl,
(14) isoquinolyl,
(15) benzofuryl,
(16) isobenzofuryl,
(17) benzothienyl,
(18) pyrazolyl,
(19) indolyl,
(2o: isoindolyl,
(21 ) purinyl,
(22) carbazolyl,
(23) > isoxazolyl,
(24: > benzthiazolyl,
(25: ► benzoxazolyl,
(26; ) thiazolyl, and
(27; ) oxazolyl. and mono and di-substituted Aryl as defined above in items (1) to (27) wherein the subs titutents are independently selected from Cl -6alkyl, Cl
6alkyloxy, hydrc >xyCl -6alkyl, Cl -6alkoxyCl -6alkyl, halo, hydroxy, amino, C l -6alky lamino, aminoCl-6alkyl, carboxyl, carboxylCl -6alkyl, and Cl -6alkylca rbonyl; comprising adding a compound of formula 9
9 wherein R2 is described as above, and L-prolinol to a solvent belonging to a group consisting of dichloromethane, benzene, toluene, cyclohexane, heptane, and carbodiimides, while maintaining a temperature of about 20°C to about 30°C to produce a solution containing a compound of structural formula 6
10 + wherein R2 is described above, adding to the solution LDA in tetrahydrofuran in the presence of DMPU, cooling the solution to from about -100°C to -50°C, adding a solution of a protected alkyl halide 5 , wherein R l is described above, and warming the solution to from about -40°C to about -20°C to produce a solution containing a compound of structural formula 11
The following Examples are intended to illustrate the preparation of compounds of Formula I, and as such are not intended to limit the invention as set forth in the claims appended, thereto.
EXAMPLE (1 ) Methyl 3-fl -Methox v- 1 -methy Dethox v-2-(5)-methylpropionate
Pyridinium /?-toluenesulfonate (2.7 mg, 0.05 mol%) was added to a stirred solution of methyl 3-hydroxy-2-(5)-methylpropionate (2.5 g, 21.2 mmol) and 2-methoxypropene (20 mL, 208 mmol) in dichloromethane (20 mL) at 0 °C. After 15 min, the solution was warmed to room temperature in 15 min and quenched with aqueous sodium hydrogencarbonate. The organic layer was separated and washed with brine, dried, and evaporated to a liquid (3.84 g, 95%): NMR (CDCI3) d 1.18 (d, J = 7.0 Hz, CH3CH), 1.32 [s, (CH3)2C], 2.69 (q, CHCH3), 3.18 fs, C(CH3)2θCH3], 3.2 and 3.61 (2 q, CH2O), 3.70 (s, COOCH3).
EXAMPLE (2) 3-( 1 -Methoxy- 1 -methyl ethoxy-2-(R -methyl- 1 -propanol
Lithium aluminum hydride (20.2 mL; 1.0 M in THF) was added to a stirred solution of (1) (3.84 g, 20.2 mmol) in THF (20 mL) at 0 °C. The solution was stirred at room temperature for 2 h and quenched sequentially with water (0.77 mL), 15% NaOH (0.77 mL), and water (2.3 mL). The resulting suspension was filtered, and the filtrate was evaporated to dryness. The residue was partitioned between CH2CI2 and brine, and the organic layer was separated, dried, and concentrated to a liquid (2.29 g, 70%):
NMR (CDCI3) d 0.89 (d, J = 7.0 Hz, CH3CH), 1.36 [s, (CH3)2C], 2.04 (m, OH), 2.76 (q, CHCH3), 3.22 [s, C(CH3)2θCH3], 3.28-3.65 (m, 2 CH2O).
EXAMPLE (3) Benzyl 3-π -Methoxy-l-methvOethoxy-2-(R)-methyl-l -propyl Ether
Potassium tert-butoxide (1.9 g, 16.9 mmol) was added to a stirred solution of (2) (2.29 g, 14.1 mmol) in THF (30 mL) at 0 oc. After 15 min, benzyl bromide (2.01 mL, 16.9 mmol) was added dropwise, and the mixture was stirred at room temperature overnight and partitioned between ethyl ether and water. The organic layer was washed with brine, dried and evaporated to an oil, which was used directly in the next experiment without further purification.
EXAMPLE (4) Benzyl 3-Hvdroxy-2-(S -methyl-l -propyl Ether
A solution of (3) from above in THF (10 mL) was treated with 2 N HCl (30 drops). After 2 h, the soluton was evaporated to a residue, which was partitioned between dichloromethane and aqueous sodium hydrogencarbonate. The organic layer was separated and washed with brine, dried, and concentrated to an oil. The crude product was purified by silica gel flash column chromatograpy (hexanes-ethyl acetate, 85: 15; v.v) to give (4) (2.07 g, 88% in 2 steps):
NMR (CDC13) d 0.88 (d, J = 7.0 Hz, CH3CH), 2.55 (m, CHCH3), 3.38- 3.65 (m, 2 CH2O), 4.53 (s, PhCH2), 7.34-7.36 (m, ArH).
EXAMPLE (5) Benzyl 3-Iodo-2-fR)-methyl-l-propyl Ether
/V-Iodosuccinimide (4.90 g, 21.78 mmol) was added portionwise to a solution of (4) (2.07 g, 12.45 mmol) and triphenylphosphine (5.71 g, 21.77 mmol) in DMF (50 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 h and heated at 40 °C for 5 min. Methanol and ti-butanol were added, and the solvents were evaporated in vacuo. The residue was partitioned between ethyl ether and water. The organic layer was washed with sodium bisulfite, brine, dried, and evaporated to dryness. The crude product was purified by silica gel flash column chromatography using hexanes-ethyl acetate (99: 1 , v/v) as the eluant. Compound (5) was isolated as a liquid (3.63 g, 77%):
NMR (CDCI3) d 0.99 (d, J = 6.8 Hz, CH3CH), 1.78 (m, CHCH3), 3.28- 3.41 (2 m, 2 CH2O), 4.52 (s, PhCH2), 7.29-7.38 (m, ArH).
EXAMPLE (6) L-Prolinol 4-(n-Propyl phenylbutanamide l -(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC; 5.58 g, 29.1 1 mmol) was added to a solution of 4- (tι-propyl)phenylbutanoic acid (5.0 g, 24.24 mmol) and (5)-2- pyrrolidinemethanol (L-prolinol; 2.39 mL, 24.35 mmol) in dichloromethane (30 mL), and the reaction mixture was stirred at room temperature overnight. Dichloromethane was added, and the solution was washed with 5 N NaOH, dil HCl, brine, dried, and evaporated to dryness. The crude product was purified by flash column chromatography (CH2Cl2-MeOH, 99: 1 ; v/v) to give (6) (5.26 g, 75%): NMR (CDCI3) d 0.93 (t, J = 7.3 Hz, CH3CH2), 2.30 (t, ArCH2), 2.55 (t, CH2CO), 2.66 (t, CH3CH2), 3.34-3.47 (m, NCH2), 3.53-3.69 (2 m, CH2OH), 4.18-4.25 (m, NCHC), 5.19 (2 d, J = 2.2 and 7.8, OH), 7.10 (br s, ArH).
EXAMPLE (7) L-Prolinol2-(3-Benzyloxy-2-(S)-methylpropyl)-4-(ti-Propyl) phenylbutanamide
LDA (1.5 M soln in cyclohexane; 10.7 mL, 16.04 mmol) was added dropwise to a solution of (6) (2.21 g, 7.64 mmol) in dry THF (20 mL) under nitrogen, and the reaction mixture was stirred at room temperature for 15 min. DMPU (1.94 mL, 16.04 mmol) was added, and the solution was cooled to -82 °C. A solution of 5 (2.1 1 g, 7.64 mmol) in dry THF (5 mL) was added dropwise. The solution was gradually warmed to -40 °C and stirred at this temperature for 4 h and kept at -20 °C ovemight. The reaction was quenched with aqueous ammonium chloride and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried, and evaporated to dryness. The crude product was purified by flash column chromatography (hexanes - ethyl acetate, 50:50; v/v) to give (7) (2.18 g, 65%): NMR (CDC13) d 0.92 (t, J = 7.3 Hz, CH3CH2), 0.95 (d, J = 6.5 HZ, CH3CH), 3.54-3.68 (2 m, CH2OH), 4.18-4.25 (m, NCHC), 4.42 (s, PhCH2), 5.30 (2 d, J = 2.2 and 7.7, OH), 7.06-7.10 (m, /7-PrArH). 7.26- 7.35 (m, ArH).
EXAMPLE (8) 2-(3-Benzyloxy-2-(S)-methylpropyl)-4-(R)-(rt-Propyl)phenylbutanoic
Acid
A solution of (7) (1.87 g, 4.27 mmol) in THF (2 mL) was added 2 N HCl (36 mL), and the mixture was heated under reflux with vigorous stirring for 34 h. The reaction was cooled to 0 °C, and 2 N NaOH (40 mL) was added. After 10 min at 0 °C, the solution was acidified with cone HCl to pH 3. The product was extracted with ethyl acetate (3 x), and the organic layer was dried and evaporated to a residue, which was purified by flash column chromatography (hexanes-ethyl acetate-acetic acid, 80:20:0.5; v/v) to give 8 (0.984 g, 62%):
NMR (CDC13) d 0.91 (t, J = 7.3 Hz, CH3CH2), 0.92 (d, J = 6.6 HZ, CH3CH), 3.21 -3.28 (m, BnOCH2), 4.44 (s, PhCH2), 7.06 (s, tz-PrArH),
7.31 -7.32 (m, ArH); MS m 1 z 351 (M + 1 ).
EXAMPLE (9) 2-(2-(S)-Benzyloxymethylpropyl)-4-(R)-(/?-Propyl)phenylbutanoyl-L- tert-Glv-NHPh
EDC (500 mg, 2.61 mmol) was added to a solution of (8) (801 mg, 2.17 mmol), L-t<?rt-Gly-NHPh (449 mg, 2.18 mmol), and 1- hydroxybenzotrizole hydrate (440 mg, 3.26 mmol) in dichloromethane (20 mL), and the mixture was stirred at room temperature overnight. The solution was washed with dil HCl, brine, dried, and evaporated to a residue, which was purified by flash column chromatography (hexanes- ethyl acetate, 85: 15 to 80:20; v/v) to give (9) (787 mg, 65%): NMR (CDCI3) d 0.91 (t, J = 7.3 Hz, CH3CH2), 0.94 (d, J = 6.6 Hz, CH3CH), 1.08 (s, t-Bu), 3.20-3.30 (m, BnOCH2), 4.45 (s, PhCH2), 4.57 (d, J = 9.2 Hz, CH/-Bu), 6.31 (d, J = 9.2 Hz, NH), 6.98-7.10, 7.22-7.34 and 7.49 (3 m, ArH), 8.33 (s, NH); MS m / z 464 (M - PhNH).
EXAMPLE (10) 2-(2-(S)-Hydroxymethylpropyl)-4-(R)-(rt-Propyl)phenylbutanoyl-L-tert-
Glv-NHPh
A solution of (9) (565 mg, 1.01 mmol) in methanol (10 mL) was hydrogenated over 20% Pd(OH)2 ( 1 13 mg) at 70 psi for 15 h. The catalyst was filtered off and washed with methanol. The combined filtrates were evaporated to a syrup (458 mg):
NMR (CDCI3) d 0.88 (d, J = 6.7 Hz, CH3CH), 0.92 (t, J = 7.4 Hz,
CH3CH2), 1.10 (s, t-Bu), 1.23-1.29 (m, CHCH2OH), 1.60 (q, CH3CH2),
1.75-2.09 (3 m, CH2CH(CO)CH2), 2.45 (m, CHCO), 2.53 and 2.60 (2 t,
2 ArCH2), 2.93, 3.25 and 3.56 (3 m, CH2OH), 4.68 (d, J = 9.2 Hz, CHt-
Bu), 6.73 (d, J = 9.2 Hz, NH), 7.02-7.09, 7.22-7.26 and 7.47-7.49 (3 ,
ArH), 8.79 (s, NHPh); MS m I z 467 (M + 1).
Anal, calcd. for C29H42N2O3: C 74.64, H 9.07, N 6.00; found: C 74.37,
H 9.14, N 5.84.
EXAMPLE (1 1 ) 2-(2-(S)-Carboxypropyl)-4-(R -(t2-Propyπphenylbutanoyl-L-t<?rt-Glv-
NHPh
Jones reagent (2.67 M; 0.586 mL, 1.57 mmol) was added dropwise to a stirred solution of ( 10) (458 mg, 0.98 mmol) in acetone (50 mL) at 0-5 °C. After 0.5 h, 2-propanol was added to destroy excess oxidant. Water (50 mL) was added, and acetone was removed in vacuo. The product was extracted with ethyl acetate (3 x). The organic layer was washed with brine, dried, and evaporated to a residue, which was purified by flash column chromatography (hexanes-ethyl acetate-acetic acid, 70:30:0.5; v/v) to give L-750,489 (333 mg, 68% overall yield in two steps):
NMR (CDC13) d 0.92 (t, CH3CH2), 1.12 (s, t-Bu), 1.13 (d, CH3CH), 1.60 (q, CH3CH2), 2.52 (t, CH3CH2CH2), 4.68 (d, J = 8.9 Hz, CHt-Bu), 6.88 (d, J = 8.9 Hz, NH), 7.00-7.08 (m ArH), 7.19 (t, ArH), 7.49 (d, ArH), 9.02 (s, NHPh); MS m I z 481 (M + 1).
Anal, calcd. for C29H40N2O4: C 72.47, H 8.39, N 5.83; found: C 72.62, H 8.41 , N 5.69.
EXAMPLE (12) (4S)-3-( 1 -Oxohexyl)-4-(phenylmethyl -2-oxazolidone n-Butyllithium (2 M soln in pentane; 77 mL, 153.8 mmol) was added dropwise to a stirred solution of (4S)-(phenylmethyl)-2- oxazolidone (25 g, 141.1 mmol) in dry THF (250 mL) at -78 oc under nitrogen. Hexanoyl chloride (21 mL, 149.5 mmol) was added portionwise, and the mixture was kept at -78 °C for 1 h and warmed to 0 °C. Saturated aqueous NaHC03 (100 mL) was added, and the mixture was stirred at 0 °C for 0.5 h. The product was extracted with dichloromethane (3 x), and the combined organic extracts were washed with 5% Na2C03 (100 mL), brine, dried, and evaporated to a syrup. The crude product was purified by flash column chromatography on silica gel (1 kg) with hexanes-ethyl acetate (97:3 to 90: 10 to 85: 15, v/v) as the eluant. The desired fractions were pooled and evaporated to an oil (36.17 g, 93%):
NMR (CDC13) d 0.90-0.94 (m, CH3), 1.35-1.39 (m, CH3CH2CH2),
1.68-1.72 (m, CH3CH2CH2CH2), 2.77 (q, J = 9.6 and 13.3 Hz,
CHCH2O), 3.30 (q, J = 3.3 and 13.3 Hz, CHCH2O), 2.93 (m, CH2CO),
4.15-4.23 (m, PhCH2), 4.64-4.70 (m, CHCH2Ph), 7.21-7.36 (m, ArH);
MS / r 276 (M -ι- l ).
Anal, calcd. for CI6H21NO3: C 69.79, H 7.69, N 5.09; found: C 69.93,
H 7.78, N 5.09.
EXAMPLE (13) (4S)-3-[ 1 -Oxo-2-(benzyloxymethyl)hexyl]-4-(phenylmethyl)-2- oxazolidone
A solution of (1 1 )(16 g, 58.1 mmol) in dry dichloromethane (1 10 mL) was cooled to 0 °C, degassed, and kept under nitrogen. Titanium(IV) chloride (1 M soln in CH2CI2; 61 mL, 61 mmol) was added portionwise to the vigorously stirred solution producing a bright yellow slution. After 5 min, triethylamine (8.5 mL, 61.3 mmol) was added dropwise giving a deep red homogeneous solution. This enolate solution was stirred at 0 °C for 1 h, after which benzyl chloromethyl ether (-80% pure; 20 mL, 1 15.5 mmol) was slowly added. The reaction mixture was stirred at this temperature for 3 h and at room temperature for 2 h over which time the dark red color faded to a pale yellow color. The reaction was quenched with saturated ammonium chloride (200 mL). The two layers were separated, and the aqueous layer was back extracted with CH2CI2 (2 x). The combined organic extracts were washed with aqueous NaHCθ3, brine, dried, and evaporated to a yellow oil. The crude product was purified by flash column chromatography (hexanes- ethyl acetate, 90:10; v/v) to give crystalline 12 (20.7 g, 90%): NMR (CDCI3) d 0.87 (t, J = 7.0 Hz, CH3CH2), 1.23-1.34 (m, CH3CH2CH2), 1.52 and 1.70 (2 m, CH3CH2CH2CH2), 2.68 and 3.23 (2 q, CHCH2O), 3.65 and 3.79 (2 q, BnOCH2), 4.12 and 4.17 (2 q, PhCH2CH), 4.24 (m, CHCO), 4.54 (q, PhCH2θ), 4.73 (m, CHCH2Ph), 7.18-7.33 (m, ArH); MS m / z 396 (M + 1).
Anal, calcd. for C24H29NO4: C 72.89, H 7.39, N 3.54; found: C 72.93, H 7.33, N 3.55.
EXAMPLE (14) 2-(S)-(Benzyloxymethyl)hexanoic Acid
A solution of (12) (12.4 g, 31.35 mmol) in THF (200 mL) and water (50 mL) was cooled to 0 °C. Hydrogen peroxide (30 wt%; 12.93 mL, 4 equiv) and lithium hydroxide monohydrate (2.64 g, 62.86 mmol) were added, and the reaction mixture was vigorously stirred at 0 °C for 1 h. A solution of sodium sulfite (17.38 g, 137. 94 mmol) in water (69 mL) and a solution of sodium hydrogencarbonate (13.16 g, 156.67 mmol) in water (230 mL) were added successively. The solution was basicified with NaOH to pH 10 and extracted with CH2C12 (3 x). The aqueous layer was acidified with HCl, and the product was extracted with ethyl acetate (3 x). The organic layer was dried and evaporated to an oil (7.08 g, 96%):
NMR (CDCI3) d 0.89 (t, CH3CH2), 1.29-1.33 (m, CH3CH2CH2), 1.54 and 1.65 (2 m, CH3CH2CH2CH2), 2.72 (m, CHCO), 3.57 and 3.66 (2 q, BnOCH2), 4.55 (s, PhCH2), 7.26-7.35 (m, ArH); MS m / z 237 (M + 1).
EXAMPLE (15) 2-(S)-(Benzyloxymethyl)hexanol
Lithium aluminum hydride (1 M soln in THF; 30 mL, 30 mmol) was added to a solution of (13) (7.08 g, 29.96 mmol) in dry THF (150 mL), and the mixture was stirred at room temperature for 2 h. Water (1.14 mL), 15% NaOH (1.14 mL), and water (3.42 mL) were added dropwise successively. The solid was was filtered off and washed with THF, and the combined filtrates were evaoprated to dryness. The residue was partitioned between dichloromethane and water. The organic layer was separated and washed with brine, dried, and evaporated to give (14) as an oil (6.56 g, 98%):
NMR (CDCI3) d 0.89 (t, J = 6.9 Hz, CH3CH2), 1.20- 1.33 [m, CH3(CH2)3l, 1.88 (m, CHCH2O), 2.63 (q, J = 4.4 and 7.0 Hz, OH), 3.46, 3.60-3.67 and 3.70-3.75 (3 m, 2 CH2O), 4.52 (q, PhCH2), 7.27- 7.37 (m, ArH); MS m / z 223 (M + 1 ). Compoun (14) can also be
prepared directly from (13) by reduction with lithium borohydride in THF.
EXAMPLE (16) 2-(5)-(Benzyloxymethyl)hexyl Iodide
-V-Iodosuccinimide (10.62 g, 47.2 mmol) was added portionwise to a stirred solution of (14) (6.56 g, 29.5 mmol) and triphenylphosphine (12.38 g, 47.2 mmol) in DMF (100 mL) at 0-5 OQ. The brown solution was stirred at room temperature for 2 h. Methanaol and n-butanol were added, and the solution was evaporated to a residue, which was partitioned between ethyl ether and water. The aqueous layer was back extracted with ethyl ether (3 x). The combined ethereal layer was washed with sodium bisulfite (2 x), brine, dried, and evaporated to a small volume. Triphenylphosphine oxide was filtered off, and the filtrate was evaporated to dryness. The cmde product was purified by flash column chromatography (hexanes-ethyl acetate, 98.5:1.5 to 98:2 to 80:20; v/v) to give (15) (7.25 g, 74%):
NMR (CDCI3) d 0.90 (t, CH3CH2), 1.20-1.37 [m, CH3(CH2)3L 3.29- 3.35 (m, CH2D, 3.42-3.45 (m, BnOCH2), 4.52 (s, PhCH2), 7.27-7.36(m, ArH).
Anal, calcd. for C14H21OI: C 50.61 , H 6.37, 1 38.20; found: C 50.89, H 6.48, 1 38.00.
EXAMPLE (17) L-Prolinol 4-(4-Fluorophenyl)phenylbutanamide
EDC (10.69 g, 55.75 mmol) was added to a solution of 4-(4- fluorophenyl)phenylbutanoic acid (12g, 46.46 mmol) and L-prolinol (4.56 mL, 46.46 mmol) in dichloromethane (200 mL), and the reaction mixture was stirred at room temperature ovemight. The solution was washed with 5 N NaOH, dil HCl, brine, dried, and evaporated to a syrup. The crude product was purified by flash column chromatography (hexanes-ethyl acetate, 50:50 to EtOAc; v/v) to give (16) (11.1 g, 70%): NMR (CDCI3) d 1.52-1.60 and 1.79-1.97 (2 m, NCCH2CH2), 2.00-2.07 (m, ArCCH2C), 2.34 (t, CH2CO), 2.73 (t, CH2Ar), 3.37-3.49 (m,
NCH2), 3.53-3.70 (2 m, CH2OH), 4.19-4.26 (m, NCHC), 5.14 (q, J = 2.3 and 7.7 Hz, OH), 7.09-7.54 (3 m, ArH); MS m / z 342 (M + 1 ). Anal, calcd. for C21H24FNO2: C 73.88, H 7.09, N 4.10, F 5.56; found: C 74.02, H 7.03, N 3.87, F 5.70.
EXAMPLE (18) L-Prolinol2-[2-(S)-(Benzyloxymethyl)hexyl]-4-(R)-(4-fluorophenyl)- phenylbutanamide
LDA (1.5 M soln in cyclohexane; 20.5 mL, 30.75 mmol) was added dropwise to a solution of (16) (5 g, 14.6 mmol) in dry THF (100 mL) under nitrogen, and the reaction mixture was stirred at room temperature for 15 min. DMPU (3.72 mL, 30.76 mmol) was added, and the solution was cooled to -82 °C. A solution of (15) (5.1 1 g, 15.4 mmol) in dry THF (40 mL) was added dropwise. The solution was gradually warmed to -40 °C and stirred at this temperature for 4 h and kept at -20 °C ovemight. The reaction was quenched with aqueous ammonium chloride and partitioned between ethyl acetate and water. The organic layer was washed with brine, dried, and evaporated to dryness. The crude product was purified by flash column chromatography (hexanes-ethyl acetate, 60:40; v/v) to give (17) (4.96 g, 62%):
NMR (CDCI3) d 0.88 (t, CH3), 1.24-1.28 [m, CH3(CH2)3 2.52-2.62 (m, CH2Ar), 2.71 -2.78 (m, CHCO), 3.52-3.69 (2 m, CH2OH), 4.21 (m, NCHC), 4.38 (s, PhCH2), 5.34 (q, 7 = 2.1 and 7.8 Hz, OH), 7.10-7.55 (3 m, ArH).
Anal, calcd. for C35H44FNO3: C 77.03, H 8.13, N 2.57, F 3.48; found: C 76.89, H 8.12, N 2.48, F 3.13.
EXAMPLE (19) 2-[2-(S)-(Benzyloxymethyl)hexyl]-4-(R)-(4-fluorophenyl)phenylbutanoic
Acid
A solution of (17) (4.74 g, 8.69 mmol) in THF (10 mL) was added 2 N HCl (100 mL), and the mixture was heated under reflux with vigorous stirring for 48 h. The solution was cooled to 0 °C and basicified
with 5 N NaOH. After 10 min at 0 °C, the solution was acidified with cone HCl to pH 3. The product and the unreacted starting material were extracted with ethyl acetate (3 x), and the organic layer was dried and evaporated to a residue, which was separated by flash column chromatography (hexanes-ethyl acetate-acetic acid, 80:20:0.5; v/v) to give unreacted (17) (0.8 g) and the product (1 ) (1.9 g, 57% based on the recovered starting material):
NMR (CDC13) d 0.86 (t, CH3), 1.17-1.29 [m, CH3(CH2)3l, 1 -33 (m, CCHC), 1.46-2.05 [4 m, CH2CH(CO)CH2) 2.54-2.75 (m, CHCO and ArCH2), 3.33 (m, BnOCH2), 4.45 (s, PhCH2), 7.08-7.53 (3 m, ArH). Anal, calcd. for C30H35FO3: C 77.89, H 7.63, F 4.1 1; found: C 77.61 , H 7.47, F 3.91.
EXAMPLE (20) 2-[2-(S)-(Benzyloxymethyl)hexyl]-4-(R)-(4-fluorophenyl) phenylbutanoyl-L-tgt-t-GlvNHMe
EDC (50 mg, 0.261 mmol) was added to a solution of (18) (100 mg, 0.216 mmol), L-tert-Gly-NHMe hydrochloride (41 mg, 0.229 mmol), N-methylmorpholine (29 L, 0.264 mmol), and 1- hydroxybenzotrizole hydrate (44 mg, 0.326 mmol) in DMF (3 mL), and the mixture was stirred at room temperature ovemight. Ethyl ether and water were added, and the aqueous layer was back extracted with ethyl ether (2 x). The combined ethereal extracts were washed with brine, dried, and evaporated to dryness. The crude product was purified by preparative TLC (hexanes-ethyl acetate, 60:40; v/v) to give (19) (94 mg, 74%):
ΝMR (CDCI3) d 0.86 (t, CH3), 0.99 (s, t-Bu), 2.79 (d, J = 4.8 Hz, ΝCH3), 3.31 (q, BnOCH2), 4.24 (d, J = 9.2 Hz, NHCHCO), 4.45 (s, PhCH2), 5.92 (br s, NHCH3), 6.19 (d, NHCH), 7.08-7.52 (3 m, ArH).
EXAMPLE (21) 2-[2-(5)-(Hydroxymethyl)hexyl]-4-(R)-(4-fluorophenyl)phenylbutanoyl-
L-tgrt-GlvNHMe
A solution of (19) (88 mg, 0.149 mmol) in methanol (3 mL) was hydrogenated over 20% Pd(OH)2 (21 mg) at 40 psi for 6 h. The catalyst was filtered off and washed with methanol. The combined filtrates were evaporated to a residue, which was purified by preparatvie TLC (hexanes-ethyl acetate, 60:40; v/v) to give (20) (61 mg, 82%): MS m I z 499 (M + 1).
EXAMPLE (22) 2-[2-(S)-(Carboxy)hexyl]-4-(R)-(4-fluorophenyl)phenylbutanoyl-L-tert-
GlvNHMe
Jones reagent (2.67 M; 66.6 mL, 0.176 mmol) was added to a stirred solution of (20) (54.4 mg, 0.109 mmol) in acetone (5 mL) at 0-5 °C. After 0.5 h, 2-propanol was added to destroy excess oxidant. Water was added, and acetone was removed in vacuo. The product was extracted with ethyl acetate (3 x). The organic layer was washed with brine, dried, and evaporated to a residue, which was purified by flash column chromatography (hexanes-ethyl acetate-acetic acid, 60:40:0.5; v/v) to give L-758,354 (46.5 mg, 83%): NMR (CDC13) d 0.88 (t, CH3), 1.04 (s, t-Bu), 1.25-1.30 [m, CH3(CH2)3 2.78 (d, J = 4.7 Hz, NCH3), 4.48 (d, J = 9.5 Hz, NHCHCO), 6.75 (br s, NHCH3), 7.01-7.42 (3 m, ArH) 7.79 (d, NHCH); MS / z 513 (M + l ).
Claims
1. A process for making a compound of structural formula I:
or a pharmaceutically acceptable salt thereof wherein:
Rl is hydrogen, substituted Cl-8alkyl, or substituted C2-8 alkenyl wherein the substituent is selected from the group consisting of:
(a) hydrogen,
(b) carboxy,
(c) Aryl wherein the Aryl group is selected from the group consisting of
(1) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) furyl,
(5) pyrryl,
(6) thienyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
(10) tetrazolyl,
(1 1) pyrazinyl,
(12) pyrimidyl,
(13) quinolyl,
(14) isoquinolyl,
(15) benzofuryl,
(16) isobenzofuryl,
(17) benzothienyl, (18) pyrazolyl,
(19) indolyl,
(20) isoindolyl,
(21) purinyl,
(22) carbazolyl,
(23) isoxazolyl,
(24) thiazolyl,
(25) oxazolyl,
(26) benzthiazolyl, and
(27) benzoxazolyl, and mono and di-substituted Aryl as defined above in items ( 1) to (27) wherein the substitutent. are independently selected from Cl -6alkyl, Cl
6alkyloxy, halo, hydroxy, amino, Cl-6alkylamino, aminoCl -6alkyl, carboxyl, carboxylCl -6alkyl, and Cl-6alkylcarbonyl;
(d)
0
II N — C — Rb
Ra
wherein Ra and Rb are each independently hydrogen; Aryl and mono and di-substituted Aryl as defined above (c); or substimted Cl-6alkyl wherein the substitutent is selected from hydroxy, halo, and phenyl, or wherein Ra and Rb are joined such that together with the nitrogen and carbon atoms to which they are attached, there is formed a saturated or unsaturated Iactam such as
wherein the Iactam portion thereof is a ring of 5, 6, 7 or 8 atoms, said Iactam or benzolactam to have a single hetero atom;
(e)
O
wherein Ra and Rb are each independently hydrogen; Aryl and mono and di-substituted Aryl as defined above (c); or substituted Ci -6alkyl wherein the substitutent is selected from hydroxy, halo, and phenyl, or wherein Ra and Rb are joined such that together with the nitrogen and carbon atoms to which they are attached, there is formed a saturated or unsaturated lactim (or imide) such as
or benzolactim (or imide) ring such as
O
(f) amino and mono or disubstituted amino wherein the substituent is selected from Cl-6 alkyl and Aryl where aryl is defined in (c);
(g)
O
II N — C — O — Rb
Ra
Wherein Ra and Rb are each independently hydrogen; or Cl-6
Alkyl; or Aryl )-6Alkyl or mono or di substituted ArylCO- 6Alkyl wherein the substitutents are independently selected from Cl -6alkyl, Cl-6alkyloxy, halo, hydroxy, amino, Ci - 6alkylamino, aminoCl -6alkyl, carboxyl, carboxylCl -6alkyl, and C l -6alky lcarbonyl and Aryl is defined as in (c); or wherein Ra and R are joined such that together with the nitrogen and oxygen atoms to which they are attached, there is formed a saturated or unsaturated monocyclic urethane or benzofused cyclic urethane such as
or
wherein the urethane ring contains 5, 6, 7 or 8 atoms, said ring to contain 2 heteroatoms;
(h)
O
II N — C — N — Rb
Ra Rc
Wherein Ra, Rb, and Rc are each independently hydrogen; or Cl-6 Alkyl; or ArylCθ-6 Alkyl or mono or di substituted ArylCθ-6Alkyl wherein the substitutents are independently selected from C i -6alkyl, Cl-6alkyloxy, halo, hydroxy, amino, C l -6alky lamino, aminoCl -6alkyl, carboxyl, carboxylCl-6alkyl, and C l -6alky lcarbonyl and Aryl is defined as in (c); or wherein Ra and Rb are joined such that together with the nitrogen atoms to which they are attached, there is formed a saturated or unsaturated monocyclic urea or benzofused cyclic urea such as
wherein the urea ring contains up to 8 atoms, said ring to contain 2 heteroatoms; or Rb and Rc are joined such that together with the nitrogen atom to which they are attached, there is formed a saturated or unsaturated monocyclic ring or benzofused ring containing 5, 6, 7 or 8 atoms, said ring to contain 1 heteroatom;
(i)
O
II
•N— S — Rb
Ra O
Wherein Ra and Rb are each independently hydrogen; or C l -6
Alkyl; or ArylCθ-6Alkyl or mono or di substituted ArylCO- 6Alkyl wherein the substitutents are independently selected from Cl-6alkyl, Cl-6alkyloxy, halo, hydroxy, amino, Cl - 6alkylamino, aminoCl-6alkyl, carboxyl, carboxylCi -6alkyl, and Ci-6alkylcarbonyl and Aryl is defined as in (c); or wherein Ra and Rb are joined such that together with the nitrogen and sulfer atoms to which they are attached, there is formed a saturated or unsaturated monocyclic sulfonaminde or benzofused cyclic sulfonamide such as
.S02 -N /
(CH2)n
or 
wherein the sulfonamide ring contains 5, 6, 7 or 8 atoms, said ring to contain 2 heteroatoms;
G) o
II C — N — Rb
I
Ra
Wherein Ra and Rb are each independently hydrogen; or C 1 -6
Alkyl; or ArylCθ-6Alkyl or mono or di substituted Aryl )- 6Alkyl wherein the substitutents are independently selected from Cl -6alkyl, Cl -6alkyloxy, halo, hydroxy, amino, Cl - 6alkylamino, aminoCl-6alkyl, carboxyl, carboxylCl -6alkyl, and Cl-6alkylcarbonyl and Aryl is defined as in (c); or Ra and Rb are joined such that together with the nitrogen atom to which they are attached, there is formed a saturated or unsaturated monocyclic ring or benzofused ring containing 5, 6, 7 or 8 atoms, said ring to contain 1 heteroatom;
( )
O
II
-s- -N — Rt
II
O R 'a.
Wherein Ra and Rb are each independently hydrogen; or Cl-6
Alkyl; or ArylCθ-6Alkyl or mono or di substituted ArylCQ- 6Alkyl wherein the substitutents are independently selected from Cl -6alkyl, Cl -6alkyloxy, halo, hydroxy, amino, Cl - 6alkylamino, aminoCl-6alkyl, carboxyl, carboxylCl -6alkyl, and Cl-6alkylcarbonyl and Aryl is defined as in (c); or Ra and Rb are joined such that together with the nitrogen atom to which they are attached, there is formed a saturated or unsaturated monocyclic ring or benzofused ring containing up to 8 atoms, said ring to contain 1 heteroatom;
R2 is Cl-12 alkyl, arylC 1 -4alkyl, aryl substituted Ci-4alkyl, (arylCi-
4alkyl)-arylCi-4alkyl, or biarylC i oalkyl wherein the substituent is Cl -
3alkyl or hydroxy, and wherein the aryl group is selected from the group consisting of:
0) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) pyrryl,
(5) furyl,
(6) thienyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
(io: ) tetrazolyl,
(i i : ) pyrazinyl,
(12: ) pyrimidyl,
(i3: ) quinolyl,
(14; ) isoquinolyl,
(i5: > benzofuryl,
(i6: ) isobenzofuryl,
(IT ) benzothienyl,
(18^ ) pyrazolyl,
(19; ) indolyl,
(2o; ) isoindolyl,
(2i; ) purinyl, (22) carboxazolyl,
(23) isoxazolyl,
(24) thiazolyl,
(25) oxazolyl,
(26) benzthiazolyl, and
(27) benzoxazolyl, and mono and di-substituted Aryl as defined above in items (1 ) to (27) wherein the substitutents on the aryl group are independently selected from Cl -6alkyl, Cl -6alkyloxy, hydroxyCi -6alkyl, Cl -6alkoxyCl -6alkyl, halo, hydroxy, amino, Cl -6alkylamino, aminoCi -6alkyl, carboxyl, carboxylCl -6alkyl, and Ci-6alkylcarbonyl;
R3 is (a) H,
(b) Z, where Z is a pharmaceutically acceptable counterion,
(c) Cl -10alkyl,
(d) Aryl or Aryl Cl-3alkyl, wherein the aryl group is selected from the group consisting of
(1 ) phenyl, and
(2) substituted phenyl, wherein the substitutent is carboxy, carboxyC l-3alkyl, aminocarbonyl, C l -6alkylaminocarbonyl;
AA is a single bond or an amino acid of formula II
(a) hydrogen,
(b) Ci-6alkyl,
(c) mercapto Ci -6alkyl,
(d) hydroxy Ci-6alkyl,
(e) carboxy C l _6alkyl,
(f) amino substituted C2-6alkyl (g) aminocarbonyl Cl-6alkyl,
(h) mono- or di-C l -6alkyl amino C2-6alkyl,
(i) guanidino C2-6alkyl,
(j) substituted phenyl Cl -6alkyl, wherein the substitutent is hydrogen.hydroxy, carboxy, Cl -4 alkyl, or CMalkyloxy, (k) substituted indolyl C l -6alkyl, wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Cl-4alkyloxy, (1) substituted imidazolyl C2-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Ci -4alkyloxy, (m) substituted pyridyl Cl -6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Cι _4alkyloxy, (n) substituted pyridylamino Cl-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or
C 1 -4alkyloxy, (o) substituted pyrimidinyl Cl-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, C 1 -4 alkyl, or
Cl-4alkyloxy,
•?» --
X is 6 wherein R5 and R6 are each individually selected from the group consisting of:
(a) H,
(b) C i-l oalkyl,
(c) Aryl or ArylC l-6alkyl, wherein the aryl group is selected from the group consisting of
(1 ) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) pyrryl,
(5) furyl,
(6) thienyl,
(7) isothiazolyl,
(8) imidazolyl, (9) benzimidazolyl,
(10) tetrazolyl,
(1 1 ) pyrazinyl,
(12) pyrimidyl,
(13) quinolyl,
(14) isoquinolyl,
(15) benzofuryl,
(16) isobenzofuryl,
(17) benzothienyl,
(18) pyrazolyl,
(19) indolyl,
(20) isoindolyl,
(21) 1 purinyl,
(22) > carbazolyl,
(23: ) isoxazolyl,
(24: ) benzthiazolyl,
(25; ι benzoxazolyl,
(26; ) thiazolyl, and
(27; ) oxazolyl. and mono and di-substituted Aryl as defined above in items (1 ) to (27) wherein the subs titutents are independently selected from Cl-6alkyl, Cl
6alkyloxy, hydroxyCl -6alkyl, Cl-6alkoxyCl-6alkyl, halo, hydroxy, amino, Cl-6alkv lamino, aminoCl-6alkyl, carboxyl, carboxylCl-6alkyl, and Cl-6alkylca rbonyl; comprising adding a compound of formula 9
2. A process according to Claim 1 wherein:
Rl is substituted Cl-8alkyl.
3. A process according to Claim 1 wherein:
the solvent belongs to a group consisting of dichloromethane, benzene, toluene, cyclohexane, heptane, and carbodiimides.
4. A process according to Claim 3 wherein: the solvent is EDC.
5. A process according to Claim 1 wherein: the strong base is LDA, LiN(SiMe3)2 or KN(SiMe3)2 .
6. A process according to Claim 1 wherein the ether is tetrahydrofuran, ethyl ether, or methyl propyl ether.
7. A process according to Claim 1 wherein: the mineral acid is HCl or H2S04.
8. A process according to Claim 6 wherein: the amount of mineral acid is from about 2 to about ION.
9. A process according to claim 5 wherein the strong acid is LDA.
10. A process according to claim 6 wherein the ether is tetrahydrofuran.
1 1. A process for making a compound of stmctural formula I:
or a pharmaceutically acceptable salt thereof wherein:
Rl is substituted Cl -8 alkyl
R2 is Cl-12 alkyl, arylCi-4alkyl, aryl substituted Cι_4alkyl, (arylCi-4alkyl)-arylCi-4alkyl, or biarylC 1 oalkyl wherein the substituent is Ci-3alkyl or hydroxy, and wherein the aryl group is selected from the group consisting of:
(1 ) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) pyrryl,
(5) furyl,
(6) thienyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
(10) tetrazolyl,
(1 1) pyrazinyl, (12) pyrimidyl,
(13) • quinolyl,
(14) isoquinolyl,
(15) benzofuryl,
(16) isobenzofuryl,
(17) 1 benzothienyl,
(is: 1 pyrazolyl,
(i9: 1 indolyl,
(20) 1 isoindolyl,
(2i; ) purinyl,
(22; ) carboxazolyl,
(23; I isoxazolyl,
(24; ) thiazolyl,
(25; ) oxazolyl,
(26; ) benzthiazolyl, and
(27; ) benzoxazolyl, and mono and di-substituted Aryl as defined above in items (1) to (27) wherein the substitutents on the aryl group are independently selected from Cl-6alkyl, Cl-6alkyloxy, hydroxyCl-6alkyl, Cl -6alkoxyCl -6aIkyl, halo, hydroxy, amino, Cl-6alkylamino, aminoCl-6alkyl, carboxyl, carboxylCl-6alkyl, and C l -6alky lcarbonyl;
R3 is (a) H,
(b) Z, where Z is a pharmaceutically acceptable counterion,
(c) Cl-lθalkyl,
(d) Aryl or Aryl Cl-3alkyl, wherein the aryl group is selected from the group consisting of
(1 ) phenyl, and
(2) substituted phenyl, wherein the substitutent is carboxy, carboxyC 1-3 alkyl, aminocarbonyl, C l -6alkylaminocarbonyl;
AA is a single bond or an amino acid of formula II 
wherein Rf and Rg are individually selected from:
(a) hydrogen,
(b) Cl-6alkyl,
(c) mercapto Cl-6alkyl,
(d) hydroxy Cl -6alkyl,
(e) carboxy Cl-6alkyl,
(f) amino substituted C2-6alkyl
(g) aminocarbonyl C l -6alkyl,
(h) mono- or di-Cl-6alkyl amino C2-6alkyl,
(i) guanidino C2-6alkyl,
(j) substituted phenyl Cl -6alkyl, wherein the substitutent is hydrogen.hydroxy, carboxy, Cl -4 alkyl, or Cl-4alkyloxy, (k) substituted indolyl Cι_6alkyl, wherein the substitutent is hydrogen, hydroxy, carboxy, Cl -4 alkyl, or Cl-4alkyloxy, (1) substituted imidazolyl C2-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Cl-4alkyloxy, (m) substituted pyridyl Cl -6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or Cl -4alkyloxy, (n) substituted pyridylamino Cl-6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or
C l -4alkyloxy, (o) substituted pyrimidinyl C 1 -6alkyl wherein the substitutent is hydrogen, hydroxy, carboxy, Cl-4 alkyl, or
Cl-4alkyloxy,
X is 6 wherein R5 and R6 are each individually selected from the group consisting of:
(a) H,
(b) Cl-ioalkyl, (c) Ary 1 or ArylC l -oalkyl, wherein the aryl group is selected from the group consisting of
(1 ) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) pyrryl,
(5) furyl,
(6) thienyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
(10) tetrazolyl,
(1 1) pyrazinyl,
(12) pyrimidyl,
(13) quinolyl,
(14) isoquinolyl,
(15) benzofuryl,
(16; 1 isobenzofuryl,
07; I benzothienyl,
(is; 1 pyrazolyl,
(i9: ) indolyl,
(2o; ) isoindolyl,
(2i ; ) purinyl,
(22 ) carbazolyl,
(23 ) isoxazolyl,
(24 ) benzthiazolyl,
(25 ) benzoxazolyl,
(26 ) thiazolyl, and
(27 ) oxazolyl. and mono and di -substituted Aryl as defined above in items (1) to (27) wherein the subs >titutents are independently selected from Cl-6alkyl, Cl
6alkyloxy, hydπ )xyCl -6alkyl, Cl -6alkoxyCl-6alkyl, halo, hydroxy, amino, Cl -6alk) amino, aminoCl-6alkyl, carboxyl, carboxylCl-6alkyl, and Cl -6alkylca rbonyl; comprising adding a compound of formula 9 
9 wherein R2 is described as above, and L-prolinol to a solvent belonging to a group consisting of dichloromethane, benzene, toluene, cyclohexane, heptane, and carbodiimides, while maintaining a temperature of about 20°C to about 30°C to produce a solution containing a compound of stmctural formula 6
' 
wherein R2 is described above, adding to the solution LDA in tetrahydrofuran in the presence of DMPU, cooling the solution to from about -100°C to -50°C, adding a solution of a protected alkyl halide 5 , wherein Rl is described above, and warming the solution to from about -40°C to about -20°C to produce a solution containing a compound of stmctural formula 11
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU73811/96A AU7381196A (en) | 1995-09-28 | 1996-09-24 | Preparation of carboxyalkyl derivatives |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US527295P | 1995-09-28 | 1995-09-28 | |
| US60/005,272 | 1995-09-28 | ||
| GB9603572.0 | 1996-02-20 | ||
| GBGB9603572.0A GB9603572D0 (en) | 1996-02-20 | 1996-02-20 | Preparation of carboxyalkyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997011936A1 true WO1997011936A1 (en) | 1997-04-03 |
Family
ID=26308768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/015672 Ceased WO1997011936A1 (en) | 1995-09-28 | 1996-09-24 | Preparation of carboxyalkyl derivatives |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU7381196A (en) |
| WO (1) | WO1997011936A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4374847A (en) * | 1980-10-27 | 1983-02-22 | Ciba-Geigy Corporation | 1-Carboxyalkanoylindoline-2-carboxylic acids |
| US4479963A (en) * | 1981-02-17 | 1984-10-30 | Ciba-Geigy Corporation | 1-Carboxyalkanoylindoline-2-carboxylic acids |
-
1996
- 1996-09-24 WO PCT/US1996/015672 patent/WO1997011936A1/en not_active Ceased
- 1996-09-24 AU AU73811/96A patent/AU7381196A/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4374847A (en) * | 1980-10-27 | 1983-02-22 | Ciba-Geigy Corporation | 1-Carboxyalkanoylindoline-2-carboxylic acids |
| US4479963A (en) * | 1981-02-17 | 1984-10-30 | Ciba-Geigy Corporation | 1-Carboxyalkanoylindoline-2-carboxylic acids |
Also Published As
| Publication number | Publication date |
|---|---|
| AU7381196A (en) | 1997-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU679474B2 (en) | Carboxy-peptidyl derivatives as antidegenerative active agents | |
| USH1992H1 (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their pharmaceutical uses | |
| JP4718172B2 (en) | Human ADAM-10 inhibitor | |
| RU2193556C2 (en) | Cyclic thio-substituted derivatives of acylamino acid amide and method of their synthesis | |
| JPH10509719A (en) | Matrix metalloprotease inhibitor | |
| DE69607615T2 (en) | INNOVATIVE METALOPROTEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| SK280939B6 (en) | Process for the synthesis of (4r-cis)-1,1-dimethylethyl-6- -cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, intermediates of this process | |
| JP4008708B2 (en) | Sulfonamide derivatives as inhibitors of matrix metalloproteinases | |
| US6340691B1 (en) | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | |
| JP2007525406A (en) | Biaryl sulfonamides and methods of use thereof | |
| JP2003531894A (en) | Biphenylbutyric acid derivatives as matrix metalloprotease inhibitors | |
| US5403952A (en) | Substituted cyclic derivatives as novel antidegenerative agents | |
| US5684152A (en) | Preparation of carboxyalkyl derivatives as inhibitors of matrix metalloproteinases | |
| JP4348014B2 (en) | N-Arylsulfonyl amino acid omega-amide | |
| KR20000052899A (en) | Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors | |
| EP2059500A2 (en) | Inhibitors of zinc proteases thioaryl substituted and their use | |
| CA2356346A1 (en) | Alkynyl containing hydroxamic acid compounds as tace inhibitors | |
| SK10112000A3 (en) | Matrix metalloprotease inhibitors | |
| WO1997011936A1 (en) | Preparation of carboxyalkyl derivatives | |
| JP5186384B2 (en) | (2,5-Dioxoimidazolidin-1-yl) -N-hydroxy-acetamide as a metalloproteinase inhibitor | |
| US5827877A (en) | Ketomethylene group-containing cysteine and serine protease inhibitors | |
| Ponpipom et al. | Chiral synthesis of C-carboxyalkyl dipeptide inhibitors of stromelysin-1 (MMP-3) | |
| KR100405913B1 (en) | Biphenyl Butyric Acid Derivative as a Matrix Metalloproteinase Inhibitor | |
| IE912848A1 (en) | Benzamide derivatives | |
| KR100405914B1 (en) | Biphenyl Butyric Acid Derivative as a Matrix Metalloproteinase Inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |